NASDAQ:CDNA CareDx Q2 2026 Earnings Report $38.37 -1.36 (-3.42%) Closing price 04:00 PM EasternExtended Trading$38.51 +0.14 (+0.36%) As of 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast CareDx EPS ResultsActual EPSN/AConsensus EPS $0.22Beat/MissN/AOne Year Ago EPSN/ACareDx Revenue ResultsActual RevenueN/AExpected Revenue$113.85 millionBeat/MissN/AYoY Revenue GrowthN/ACareDx Announcement DetailsQuarterQ2 2026Date7/30/2026TimeAfter Market ClosesConference Call DateThursday, July 30, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile CareDx Earnings HeadlinesCareDx's Growth Prospects With Naveris Keep Me BullishJuly 20 at 9:00 AM | seekingalpha.comCareDx (CDNA) Stock May Be Fully Valued Despite Medicare Coverage NewsJuly 18 at 12:21 AM | finance.yahoo.comDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December.July 20 at 1:00 AM | Porter & Company (Ad)CareDx (CDNA) Is Up 39.4% After Medicare Clarifies Transplant Test Coverage Limits - What's ChangedJuly 18 at 12:21 AM | finance.yahoo.comBTIG Research Forecasts Strong Price Appreciation for CareDx (NASDAQ:CDNA) StockJuly 18 at 2:36 AM | americanbankingnews.comCareDx rallies after Medicare finalizes transplant testing coverage policyJuly 16, 2026 | msn.comSee More CareDx Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CareDx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CareDx and other key companies, straight to your email. Email Address About CareDxCareDx (NASDAQ:CDNA) (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey. The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring. CareDx also offers a range of clinical laboratory services and companion diagnostic solutions that support patient management in lung and liver transplantation. Headquartered in Brisbane, California, CareDx serves transplant centers across the United States, Europe and select international markets. The company operates a network of CLIA‐certified laboratories and collaborates with academic institutions and transplant centers to advance research in immunological monitoring and personalized patient care. CareDx was established through the integration of Viracor-IBT and Transplant Genomics in 2018, building on more than a decade of molecular diagnostic expertise. The company’s leadership team comprises seasoned professionals with backgrounds in biotechnology, laboratory operations and clinical research, all dedicated to improving outcomes for transplant recipients worldwide.View CareDx ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Is Domino's Stock Serving Up a Buying Opportunity?Meta Platforms Turns AI Power Scarcity Into a $10 Billion Cloud BetAmazon’s AI Spending Is About to Face Its Most Important AWS Test YetMarketBeat Week in Review – 07/13- 07/17Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to BenefitBank Earnings Are Roaring, But Wall Street Isn't Ready to CelebrateThe Market Sold Alcoa After Earnings—But It May Be Missing the Real Story Upcoming Earnings General Motors (7/21/2026)Northrop Grumman (7/21/2026)America Movil (7/21/2026)Alphabet (7/21/2026)Chubb (7/21/2026)Capital One Financial (7/21/2026)Interactive Brokers Group (7/21/2026)Charles Schwab (7/21/2026)Danaher (7/21/2026)Novartis (7/21/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
